| abstract |
The present invention relates to fusion proteins comprising GDF15 variants with increased bioactivity and in vivo stability, and pharmaceutical compositions comprising same. The GDF15 mutants or long-acting GDF15 fusion proteins according to the invention are superior to conventional GDF15 mutants in terms of in vitro potency, binding affinity to the GDF15 receptor and weight loss effect. Accordingly, pharmaceutical compositions of the present invention comprising, as an active ingredient, a GDF15 variant, a long-acting GDF15 fusion protein, or a dimer of the fusion protein, cause appetite suppression and are therefore therapeutic agents for metabolic diseases or obesity. can be effectively used as Furthermore, pharmaceutical compositions comprising the GDF15 variant, long-acting GDF15 fusion protein, or fusion protein dimer as an active ingredient may be used in combination therapy with chemical agents and other drugs for treating metabolic diseases. and can be effectively used in combination therapy with conventional therapeutic agents for metabolic disease or obesity. |